Skip to content

EU · EudraLex Vol.4

EU GMP Part I, Chapter 8 8.9

Personnel and Organisation

Section text

When a quality defect investigation is initiated, procedures should be in place to address at least the following:

i. The description of the reported quality defect.

ii. The determination of the extent of the quality defect. The checking or testing of reference and/or retention samples should be considered as part of this, and in certain cases, a review of the batch production record, the batch certification record and the batch distribution records (especially for temperature-sensitive products) should be performed.

iii. The need to request a sample, or the return, of the defective product from the complainant and, where a sample is provided, the need for an appropriate evaluation to be carried out.

iv. The assessment of the risk(s) posed by the quality defect, based on the severity and extent of the quality defect.

v. The decision-making process that is to be used concerning the potential need for risk-reducing actions to be taken in the distribution network, such as batch or product recalls, or other actions.

vi. The assessment of the impact that any recall action may have on the availability of the medicinal product to patients/animals in any affected market, and the need to notify the relevant authorities of such impact.

vii. The internal and external communications that should be made in relation to a quality defect and its investigation.

viii. The identification of the potential root cause(s) of the quality defect.

ix. The need for appropriate Corrective and Preventative Actions (CAPAs) to be identified and implemented for the issue, and for the assessment of the effectiveness of those CAPAs.

3 Investigation and Decision-making

Source: European Commission, DG SANTE · © European Union. Reuse is authorised provided the source is acknowledged (Commission Decision 2011/833/EU on the reuse of Commission documents). · retrieved 2026-11-15

Weekly Newsletter

Get new findings like these every Monday

Every Monday we email the week's new findings and actions from the FDA, EMA, Health Canada and MFDS. Each one links to its record on our site, where you'll find the regulator's original document. We'll also let you know when the site gains new features. Unsubscribe any time with one click.

See recent findings first

Sent every Monday · a confirmation email follows when you subscribe · unsubscribe from the footer of any email.